C - Chemistry – Metallurgy – 07 – D
Patent
C - Chemistry, Metallurgy
07
D
C07D 495/04 (2006.01) A61K 31/519 (2006.01) A61P 3/04 (2006.01) A61P 25/00 (2006.01)
Patent
CA 2644996
The present invention relates to novel compounds that are A2A adenosine receptor antagonists of the formula I, and to their use in treating mammals for various disease states, such as obesity, CNS disorders, including the "movement disorders" (Parkinson's disease, Huntington's Chorea, and catelepsy), and cerebral ischemia, excitotoxicity, cognitive and physiological disorders, depression, ADHD, and drug addiction (alcohol, amphetamine, cannabinoids, cocaine, nicotine, and opioids) and to their use in the enhancement of immune response. The invention also relates to methods for the preparation of such compounds, and to pharmaceutical compositions containing them.
La présente invention concerne de nouveaux composés qui sont des antagonistes du récepteur A2A de l'adénosine, et leur utilisation dans le cadre du traitement de divers états pathologiques chez les mammifères, tels que l'obésité, les troubles du SNC, y compris les 'troubles du mouvement' (la maladie de Parkinson, la chorée d'Huntington, et la catalepsie), et l'ischémie cérébrale, l'excitotoxicité, les troubles cognitifs et physiologiques, la dépression, le TDAH et la toxicomanie (alcool, amphétamine, cannabinoïdes, cocaïne, nicotine et opioïdes), et leur utilisation pour l'amplification de la réponse immunitaire. L'invention concerne également des procédés de préparation de tels composés et des compositions pharmaceutiques les contenant.
Elzein Elfatih
Kalla Rao
Kobayashi Tetsuya
Li Xiaofen
Parkhill Eric
Cv Therapeutics Inc.
Gilead Palo Alto Inc.
Mbm Intellectual Property Law Llp
LandOfFree
A2a adenosine receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with A2a adenosine receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and A2a adenosine receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1480924